uniQure Won the Filing and Lost the Argument — and the Stock Knows Which One Matters
A priority-review BLA, a validated UK application, a May 1 2027 PDUFA date… and a 55% drawdown since August, because the confirmatory trial is starting from a cold stop and the FDA wants an AdCom.
QURE · Earnings Call · 2026-11-04
The acceptance landed; the equity didn't
On Monday the FDA accepted uniQure's BLA for AMT-130 in Huntington's disease and granted priority review, with a PDUFA date of May 1, 2027; the MHRA validated the UK marketing application the same week. It is, on paper, the biggest de-risking event in the company's history — the first marketing applications ever filed for a disease-modifying HD therapy. Matt Kapusta did not undersell it: “the FDA has accepted our biologics license application for AMT-130 and granted priority review with a target PDUFA date of May 1, 2027” — Matthew Kapusta, Chief Executive Officer · 2026-11-04.
The tape disagrees violently. QURE is down 50% over the last ninety trading days and 54.9% from its August 25 peak of $51.05, still 72% below the 2019 high of $82.19. Note the timing: the decline began at the end of August, weeks before this acceptance. Priority review was the base case — management had flagged a “reasonable chance” — Matthew Kapusta, Chief Executive Officer (CEO) · 2026-07-29 of it back in July. So the acceptance was largely pre-paid, and what the market is now pricing is everything that arrived attached to it: a tentatively scheduled advisory committee, and a confirmatory study that is only now submitting protocols to IRBs.
The argument that quietly disappeared
Here is the real change this quarter, and it is not in the headline. In March, Walid Abi-Saab described the design negotiation as a fight the company was losing:
the FDA was very clear about their strong recommendation to do a double-blind sham-controlled trial, that is adequately powered
. The sham control debate was, at the time, the single highest-momentum keyword in the company's language — the entire 2026Q1 call was a plea for regulatory flexibility around external controls, Enroll-HD, and propensity-score matching.
That vocabulary is gone. Not softened — gone. Sham control, external control, propensity score, Enroll-HD: none appear in this quarter's top keyword set, and the argument has resolved into something far more conventional and far more expensive:
this will be a randomized study with a 2:1 ratio of AMT-130 high dose to standard of care. It will include approximately 200 patients. The primary endpoint is TFC at 36-month. After 36-month, all standard of care participants will be offered AMT-130 in a separate open-label study
No sham surgery. A two-arm, 200-patient, 36-month functional-endpoint study across North America, Europe and Latin America. uniQure won the argument about what the filing could rest on — the 36-month cUHDRS analysis against a matched external control, the same package the FDA blessed in writing back in November 2024, when management confirmed it “may serve as the primary basis of a BLA submission” — Matthew Kapusta, Chief Executive Officer · 2025-11-10. It conceded the argument about what confirmation requires. That is a real trade, and it is a better trade than a sham — but 200 randomized patients, screening not yet begun, with a decision date seven months away, is a thin answer to the FDA's insistence that the study be meaningfully underway.
Watch also the endpoint migration. Primary endpoint now means TFC at 36 months, not the composite that carried the Phase I/II. That is consistent with what the company said in July about the agency's philosophical preference for pure functional measures — but it means the confirmatory study will be judged on a different instrument than the one that got the drug filed.
A new vocabulary: process, not people
The freshest keywords of the quarter are bureaucratic, and that tells you where the story now lives: day 74 letters, the briefing book, active review, NHS England commissioning, and — the one the company has bet its launch on — HDSA Centers of Excellence.
What has dropped out matters as much. "HD community" was among the biggest momentum decliners of the quarter; the patient-advocacy framing that carried the 2025–2026 campaign has given way to disclosure discipline. “going forward, we will not be commenting on specific information requests made by the FDA, including questions regarding a potential AdCom” — Walid Abi-Saab, Chief Medical Officer · 2026-11-04. A company that spent five quarters telling investors its FDA feedback was clear and unambiguous now has a quiet period it did not choose. Analysts probed the gap directly — the day 74 letter, whether the four-year data could trigger a major amendment — and got the same answer each time. On the definition of "well underway" the CEO fell back on discretion: “the FDA does have a wide discretion to determine what is meaningfully underway” — Matthew Kapusta, Chief Executive Officer · 2026-11-04.
A genuinely new concern keyword also surfaced: dropout. For the first time the question is not whether the trial can enroll, but whether the standard-of-care arm will stay enrolled once the drug is commercially available in the US. Walid's answer — prioritize US enrolment early, then shift to countries where AMT-130 is not yet sold — is the same answer he gave in July, when he described the retention plan in detail. The mechanism has not changed; the urgency has.
Launch gates on operating rooms, not demand
Kylie O'Keefe's commercial section is the most concrete part of the call, and it reframes the launch as a capacity problem. HD care is concentrated — 35,000 diagnosed patients, most seen at specialty clinics — so “we're certainly going to be north of 15 centers. Could it be 30? Could it be 25? We're still working through that” — Kylie O'Keefe, Head of Commercial Operations · 2026-11-04. Against 60-plus HDSA centers and over 100 with ClearPoint capability, the constraint is P&T committee timing and neurosurgeon throughput, which she described as ranging from two procedures a week to one a month. Kapusta added that manufacturing will not bind: dosing is roughly 500 microliters per infusion, so per-batch patient yields far exceed an IV-administered gene therapy.
The financials support the build. Q3 revenue of $5.2 million against $3.7 million, R&D of $35.5 million, SG&A up $4.5 million to $23.9 million on hiring, and $768.4 million of cash and investment securities at September 30, up from $622.5 million at year end, funding operations into 2030. The filings through June show the other side of the ledger: quarterly revenue of roughly $6 million, an operating loss near $79 million, and a valuation of about 171 times trailing revenue. Solvency has improved sharply — liabilities are down to 67% of assets from a 96.9% peak.
The divergence worth noting
Across the market, regulatory-catalyst themes have been among the better performers of the past year — PDUFA target action date names like LGND, JAZZ and MRK have compounded strongly. uniQure owns the cleanest such catalyst in rare disease and trades as if it owns the risk instead. That is the honest read of this report: the filing is done, the argument about evidence has been settled in the company's favour, and every remaining uncertainty — an AdCom on 36 versus 48 months, a first patient screened by year end, a centre network built one P&T committee at a time — has been pushed into the seven months before May 1. Nothing in the P&L changed much this quarter. Everything about the risk profile did.